CBX2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL30315936	1.00	1/20
SCHEMBL29613505	0.91	1/20
SCHEMBL27223064	0.89	1/20
SCHEMBL27232005	0.89	1/20
SCHEMBL23682719	0.73	1/20
SCHEMBL23682865	0.73	1/20
SCHEMBL23717921	0.73	1/20
SCHEMBL23718040	0.73	1/20
SCHEMBL26219950	0.73	1/20
SCHEMBL29613468	0.71	1/20
SCHEMBL29613457	0.71	1/20
SCHEMBL24511108	0.68	1/20
SCHEMBL23718039	0.64	1/20
SCHEMBL23815796	0.64	1/20
SCHEMBL23815561	0.64	1/20
SCHEMBL24510752	0.64	1/20
SCHEMBL23682687	0.63	1/20
SCHEMBL23815823	0.63	1/20
SCHEMBL24510644	0.63	1/20
SCHEMBL29613443	0.63	1/20

Clinical trials — most relevant to CBX2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure	PHASE2	COMPLETED
Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer	PHASE1/PHASE2	SUSPENDED
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)	PHASE2	ACTIVE_NOT_RECRUITING
Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer	PHASE1/PHASE2	WITHDRAWN
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis	PHASE1/PHASE2	RECRUITING
Phase II Study of Vandetanib in Individuals With Kidney Cancer	PHASE2	COMPLETED
A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer	PHASE2	UNKNOWN
Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma	PHASE2	ACTIVE_NOT_RECRUITING
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Decitabine in Treating Patients With Myelofibrosis	PHASE2	ACTIVE_NOT_RECRUITING
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Genetic Clues to Chordoma Etiology: A Protocol to Identify Sporadic Chordoma Patients for Studies of Cancer-Susceptibility Genes	nan	ACTIVE_NOT_RECRUITING
X-chromosome Inactivation, Epigenetics and the Transcriptome	nan	COMPLETED
Immunophenotyping and Xist Gene in AML	nan	UNKNOWN
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients	nan	RECRUITING
Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies	nan	WITHDRAWN
Tissue Bank of Biological Specimens From Patients With Gynecologic Disease	nan	UNKNOWN
Multicenter Study of 18F-Labeled NY104 for PET/CT Imaging in Renal Cell Carcinoma	nan	RECRUITING
Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants	nan	RECRUITING
Diaphragmatic Hernia Research & Exploration, Advancing Molecular Science	nan	RECRUITING
Genetic Study of Newly Diagnosed Central Nervous System Tumors in Young Children	nan	COMPLETED
Gene Mutations and Rescue in Human Congenital Diaphragmatic Hernia	nan	UNKNOWN
Different Genetic Features Associated With Hepatic Carcinogenesis	nan	UNKNOWN
Characterization of At-risk Population for Pre-sacral Tumor in CURRARINO Syndrome	nan	COMPLETED
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia	nan	COMPLETED
Genetic Study of Familial Epilepsy	nan	COMPLETED
Target of Suv420h1/2 in Hepatocytes	nan	RECRUITING
Genomic Study of Congenital Malformation	nan	UNKNOWN
A Study of Multilocus Methylation Abnormalities in Subjects With Imprinting Disorders	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a CBX2 binder may also engage these)

Protein	Name	Similarity
P30658	—	1.000	P30658 →
Q8BZ32	—	0.995	Q8BZ32 →
KDM3B	Lysine-specific demethylase 3B	0.995	landscape →
CBX4	E3 SUMO-protein ligase CBX4	0.994	landscape →
Q5YCW0	—	0.992	Q5YCW0 →
O88737	—	0.990	O88737 →
P19332	—	0.990	P19332 →
Q9JL04	—	0.990	Q9JL04 →
TET3	Methylcytosine dioxygenase TET3	0.990	landscape →
P48382	—	0.990	P48382 →
Q5S6V2	—	0.989	Q5S6V2 →
Q5YCW1	—	0.989	Q5YCW1 →
MAPT	Microtubule-associated protein tau	0.989	landscape →
Q3UHR0	—	0.989	Q3UHR0 →
MIDEAS	Mitotic deacetylase-associated SANT domain protein	0.989	landscape →
O08696	—	0.989	O08696 →
Q9Y6X0	—	0.989	Q9Y6X0 →
Q5VZ18	—	0.989	Q5VZ18 →
Q6ZPY7	—	0.988	Q6ZPY7 →
Q9Z180	—	0.988	Q9Z180 →
Q9NPG3	—	0.988	Q9NPG3 →
A2VDR9	—	0.988	A2VDR9 →
Q5YCV9	—	0.988	Q5YCV9 →
Q9DBY5	—	0.988	Q9DBY5 →
Q76L83	—	0.988	Q76L83 →
Q29RJ9	—	0.988	Q29RJ9 →
Q9CWL2	—	0.988	Q9CWL2 →
O54963	—	0.988	O54963 →
Q3KR66	—	0.988	Q3KR66 →
Q96RK0	—	0.988	Q96RK0 →